All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2016-11-18T18:51:27.000Z

The AGP will be at ASH 2016 – 2 weeks to go!!

Nov 18, 2016
Share:

Bookmark this article

There are only 14 days left until the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH).

For over 50 years, the ASH annual meeting has been considered the premier event for the exchange of scientific knowledge, specifically in the field of malignant and non-malignant hematology. This event is typically attended by more than 20,000 hematology professionals, from every speciality, from across the globe making it the perfect opportunity to network with the top minds in the field. Each year, ASH receive over 5,000 abstracts for this event, of which over 3,000 pass the extensive peer review process and are accepted for poster and oral presentations. The highlight of the event is considered to be the Plenary Scientific Session, where the top 6 abstracts, selected by the Program Committee, are presented and discussed.

The AML Global Portal (AGP) had a fantastic few days reporting live from ASH 2015, held in Orlando. We live reported and tweeted each day on a number of exciting sessions which focused on a range of different topics including:

  • Advances in therapy
  • Advances in targeted therapy
  • New approaches using older drugs
  • Novel therapy (excluding transplantation)

Other interesting presentations included clinical and molecular characterization of p53-mutated AML, a Satellite Symposia on novel and emerging therapeutics, and numerous presentations on SGN-CD33A demonstrating anti-leukemic activity in Acute Myeloid Leukemia (AML).

In addition, at last year’s event, the AGP interviewed top experts in the field of malignant hematology; we discussed results of the CALGB 10603/RATIFY study with Dr Richard Stone, we interviewed Prof. Rüdiger Hehlmann on activities of the European LeukemiaNet (ELN) and future challenges the ELN faces, and we asked Dr Paul Ferguson what is his definition of Primary Refractory AML.

This year’s ASH Annual Meeting & Exposition is taking place at the San Diego Convention Center, California, from 3–6 December, and the AGP will be there. Be sure to visit The AML Global Portal for coverage of oral abstracts, educational sessions, and interviews with speakers and our Steering Committee members.

More about...

Your opinion matters

Do you intend to implement next-generation sequencing for measurable residual disease monitoring in MDS patients?
1 vote - 4 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox